Special Issue "Hormone Therapy"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (30 June 2012)

Special Issue Editor

Guest Editor
Dr. John Eden
Department of Reproductive Endocrinology, The University of New South Wiles, Sydney, Australia
Website: http://www.whria.com.au/
E-Mail: j.eden@unsw.edu.au
Interests: menopause after breast cancer; polycystic ovary syndrome (PCOS); osteoporosis; biofilms; hormone replacement therapy as well as herbal medicine

Special Issue Information

Dear Colleagues,

Some years ago HT was being touted as a treatment for most if not all menopausal women to treat symptoms such as hot flushes as well as a preventive agent for heart disease and osteoporosis. However, since the first publication of the results of the Women's Health Initiative (WHI) in July 2002, HT usage has declined substantially. Much of the female population is now fearful that HT usage may increase their risk of breast cancer. Around a quarter of women will have severe menopausal symptoms as they pass through the menopause transition and some will have symptoms for the rest of their lives. How safe is HRT? How should we manage women who have severe menopausal flushing for years? Which is the best method for managing genitourinary symptoms? These are some of the questions being addressed this this issue.

Dr. John Eden
Guest Edtor

Keywords

  • oestrogen
  • estrogen
  • progesterone
  • progestin
  • hormone therapy
  • hormone replacement therapy
  • menopause
  • flushes
  • flashes
  • women's health initiative
  • nurse's health study
  • million women
  • studytestosterone (replacement)
  • androgen (replacement)
  • steroids

Published Papers (4 papers)

by , , ,  and
Pharmaceuticals 2012, 5(10), 1120-1127; doi:10.3390/ph5101120
Received: 8 July 2012; in revised form: 4 October 2012 / Accepted: 15 October 2012 / Published: 22 October 2012
Show/Hide Abstract | PDF Full-text (182 KB) | HTML Full-text | XML Full-text
abstract graphic

by  and
Pharmaceuticals 2012, 5(9), 899-924; doi:10.3390/ph5090899
Received: 2 July 2012; in revised form: 18 August 2012 / Accepted: 24 August 2012 / Published: 4 September 2012
Show/Hide Abstract | Cited by 1 | PDF Full-text (256 KB) | HTML Full-text | XML Full-text

by , , , , ,  and
Pharmaceuticals 2012, 5(7), 758-778; doi:10.3390/ph5070758
Received: 4 June 2012; in revised form: 9 July 2012 / Accepted: 12 July 2012 / Published: 19 July 2012
Show/Hide Abstract | PDF Full-text (763 KB) | HTML Full-text | XML Full-text
abstract graphic

by ,  and
Pharmaceuticals 2011, 4(5), 726-740; doi:10.3390/ph4050726
Received: 12 April 2011; in revised form: 5 May 2011 / Accepted: 10 May 2011 / Published: 16 May 2011
Show/Hide Abstract | Cited by 1 | PDF Full-text (205 KB) | HTML Full-text | XML Full-text

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert